Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 79 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects aged from 20 years to under 80 years on the day informed consent is obtained
Subjects to whom the study drugs can be orally administered within 72 hours after the onset of rash due to herpes zoster
Subjects in whom protocol-specified observations and assessments are considered possible
Subjects with extremely compromised immune function due to underlying diseases, treatment with Immunosuppressive agents etc., or radiotherapy
Subjects with a serious underlying disease that corresponds to Grade 3 in the Classification Criteria for teh Seriousness of Adverse Drug Reactions
Subjects with concurrent malignant tumors, or those with a history of malignant tumors within the past 5 years